Browsing Tag
cancer therapeutics
4 posts
Why TROP2 ADC competition may hinge on payload differentiation after AKTX-101 data
Find out how AKTX-101 could reshape TROP2 ADC competition and what it means for oncology investors and strategy.
How a proenzyme-based approach from Propanc Biopharma tests the limits of current solid tumor paradigms
Can a proenzyme therapy reshape solid tumor treatment models? Explore what Propanc Biopharma’s PRP strategy signals for oncology markets.
Jacobio Pharma secures $2bn global licensing agreement with AstraZeneca for JAB-23E73
Jacobio Pharma’s $2B global licensing deal with AstraZeneca could reshape KRAS inhibitor strategy in oncology. Read the full breakdown of the partnership now.
Why Hemispherian’s FDA-cleared GLIX1 trial could be a turning point for brain cancer therapy
Hemispherian gets FDA clearance for GLIX1 Phase 1 trial in glioblastoma. Find out how this novel therapy targets DNA repair to combat deadly brain tumors.